{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:57:55Z","timestamp":1793127475349,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grants-in-Aid for Scientific Research on Priority Areas","award":["15K16362"],"award-info":[{"award-number":["15K16362"]}]},{"name":"Grants-in-Aid for Scientific Research on Priority Areas","award":["15K16362"],"award-info":[{"award-number":["15K16362"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mild cognitive impairment in Parkinson\u2019s disease (PD-MCI) is associated with an increased risk of cognitive decline. PD-MCI is characterized by impairments in executive function and visuospatial recognition. The visuospatial n-back test is useful for assessing both domains. The 0-back test reflects visuospatial recognition, while the 1-back and 2-back tests reflect working memory. Cholinesterase inhibitors are effective in the treatment of PD-MCI and dementia in PD (PDD). Although some studies have reported the efficacy of memantine for PDD, the therapeutic efficacy of memantine in patients with PD-MCI remains uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study aimed to investigate the effects of memantine on brain function in patients with PD-MCI, using a randomized double-blinded crossover protocol and functional MRI (fMRI). Ten patients who completed 16\u2009weeks of follow-up were included. They were randomly assigned to either the memantine or placebo. Patients in the memantine group received 5\u2009mg\/day of memantine in the first week. The memantine dose was increased by 5\u2009mg\/day per week, until a final dose of 20\u2009mg\/day. Patients in the placebo group received the placebo following the same regimen as memantine. After the intervention, they underwent a 4\u2009weeks washout period. Following the crossover protocol, a second intervention was conducted after the washout period. In each intervention, fMRI and neuropsychological tests were performed at the maximum dose period. Comparing the memantine and placebo groups, we investigated difference in the brain regions using the visuospatial n-back test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no significant regions enhanced by memantine comparing with placebo at any load of n-back tests. In contrast, exploring regions reduced by memantine, we found significant reduction of activations within right lingual gyrus and left superior frontal gyrus in comparison between 2-back and 0-back test. A number of correct answers of the 2-back test and time to complete Trail Making Test-A were worse during memantine intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Memantine did not improve visuospatial working memory of the patients with PD-MCI. Treatment for PD should be planned carefully considering the impact on cognitive function. Further study is needed to establish new therapeutic strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>UMIN000046104. Retrospectively registered.<\/jats:p><jats:p>First registration date: 28 Sept 2017.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-022-02699-x","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T07:03:16Z","timestamp":1652425396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Memantine for the patients with mild cognitive impairment in Parkinson\u2019s disease: a pharmacological fMRI study"],"prefix":"10.1186","volume":"22","author":[{"given":"Shoji","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"RCIP-Nagoya Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuya","family":"Horiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Akanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruaki","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kunitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenari","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"6","key":"2699_CR1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-S\u00f8rensen P. Risk of dementia in Parkinson\u2019s disease: a community-based, prospective study. Neurology. 2001;56(6):730\u20136.","journal-title":"Neurology"},{"issue":"12","key":"2699_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","volume":"75","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062\u20139.","journal-title":"Neurology"},{"issue":"3","key":"2699_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000068483","volume":"15","author":"C Janvin","year":"2003","unstructured":"Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients with Parkinson\u2019s disease without dementia. Dement Geriatr Cogn Disord. 2003;15(3):126\u201331.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"2699_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0000000000003634","volume":"88","author":"KF Pedersen","year":"2017","unstructured":"Pedersen KF, Larsen JP, Tysnes O-B, Alves G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology. 2017;88(8):767\u201374.","journal-title":"Neurology"},{"issue":"1","key":"2699_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jnnp-2013-305062","volume":"85","author":"JE Lee","year":"2013","unstructured":"Lee JE, Cho KH, Song SK, Kim HJ, Lee HS, Sohn YH, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013;85(1):7\u201316.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2699_CR6","first-page":"1","volume":"132","author":"A Hui","year":"2019","unstructured":"Hui A, He W, Wu J, Junjun Z, Zhenlan J, Li L. A coordinate-based meta-analysis of the n-back working memory paradigm using activation likelihood estimation. Brain Cogn. 2019;132(7):1\u201312.","journal-title":"Brain Cogn"},{"key":"2699_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/cercor\/bhn095","volume":"19","author":"SM Landau","year":"2009","unstructured":"Landau SM, Lal R, O\u2019Neil JP, Baker S, Jagust WJ. Striatal dopamine and working memory. Cereb Cortex. 2009;19:445\u201354.","journal-title":"Cereb Cortex"},{"key":"2699_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.1204978","volume":"333","author":"L Backman","year":"2011","unstructured":"Backman L, Nyberg L, Soveri A, Johansson J, Andersson M, Dahlin E, et al. Effects of working-memory training on striatal dopamine release. Science. 2011;333:718.","journal-title":"Science"},{"issue":"5355","key":"2699_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1126\/science.279.5355.1347","volume":"279","author":"SM Courtney","year":"1998","unstructured":"Courtney SM, Petit L, Maisog JM, Ungerleider LG, Haxby JV. An area specialized for spatial working memory in human frontal cortex. Science. 1998;279(5355):1347\u201351.","journal-title":"Science"},{"issue":"8","key":"2699_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/cercor\/8.8.743","volume":"8","author":"S Carlson","year":"1998","unstructured":"Carlson S, Martinkauppi S, Rama P, Salli E, Korvenoja A, Aronen HJ. Distribution of cortical activation during visuospatial n-back tasks as revealed by functional magnetic resonance imaging. Cereb Cortex. 1998;8(8):743\u201352.","journal-title":"Cereb Cortex"},{"issue":"1","key":"2699_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-021-02366-7","volume":"21","author":"K Shoji","year":"2021","unstructured":"Shoji K, Yoko S, Yoshino U, Noriyuki M. Impairment of the visuospatial working memory of the patients with Parkinson\u2019s disease. BMC Neurol. 2021;21(1):335.","journal-title":"BMC Neurol"},{"key":"2699_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2174\/156720510791383877","volume":"7","author":"WJ McGeown","year":"2010","unstructured":"McGeown WJ, Shanks MF, Forbes-McKay KE, Waiter GD, Elrick I, Venneri MG, et al. Established donepezil treatment modulates regional brain activation in early Alzheimer\u2019s disease. Curr Alzheimer Res. 2010;7:415\u201327.","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"2699_CR13","doi-asserted-by":"publisher","first-page":"e96806","DOI":"10.1371\/journal.pone.0096806","volume":"9","author":"N Tambasco","year":"2014","unstructured":"Tambasco N, Muti M, Chiarini P, Tarducci R, Caproni S, Castorioto A, et al. Entacapone reduces cortical activation in Parkinson\u2019s disease with wearing-off: a f-MRI study. PLoS One. 2014;9(5):e96806.","journal-title":"PLoS One"},{"issue":"4","key":"2699_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4):587\u201398.","journal-title":"Ann Neurol"},{"issue":"4","key":"2699_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/syn.890190405","volume":"19","author":"MS Starr","year":"1995","unstructured":"Starr MS. Glutamate\/dopamine D1\/D2 balance in the basal ganglia and its relevance to Parkinson\u2019 disease. Synapse. 1995;19(4):264\u201393.","journal-title":"Synapse"},{"issue":"3","key":"2699_CR16","first-page":"CD006504","volume":"2012","author":"M Rolinski","year":"2012","unstructured":"Rolinski M, Fox C, Maidment I, Mcshane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;2012(3):CD006504.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2699_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/11594110-000000000-00000","volume":"28","author":"C Ballard","year":"2011","unstructured":"Ballard C, Kahn Z, Corbett A. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging. 2011;28(10):769\u201377.","journal-title":"Drugs Aging"},{"issue":"14","key":"2699_CR18","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa066583","volume":"357","author":"JH Robert","year":"2007","unstructured":"Robert JH, Edmund J, Clive GB, Peter B, Richard GB, Roger B, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357(14):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"7496","key":"2699_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","volume":"330","author":"B Clive","year":"2005","unstructured":"Clive B, Marisa ML, Edmund J, Simon D, Alan S, Alan T, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.","journal-title":"BMJ"},{"issue":"14)","key":"2699_CR20","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stiffler A, Schmitt F, Ferris S, Jorg H, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14)):1333\u201341.","journal-title":"N Engl J Med"},{"issue":"4","key":"2699_CR21","doi-asserted-by":"publisher","first-page":"e0123289","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"M Shinji","year":"2015","unstructured":"Shinji M, Taro K, Nakao I. Memantine Monotherapy for Alzheimer\u2019s disease: a systematic review and Meta-analysis. PLoS One. 2015;10(4):e0123289.","journal-title":"PLoS One"},{"issue":"10","key":"2699_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, Dest\u00e9e A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"issue":"6","key":"2699_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","volume":"42","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42(6):1142\u20136.","journal-title":"Neurology."},{"issue":"14","key":"2699_CR24","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/mds.25655","volume":"28","author":"JG Goldman","year":"2013","unstructured":"Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society task force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013;28(14):1972\u20139.","journal-title":"Mov Disord"},{"issue":"3","key":"2699_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349\u201356.","journal-title":"Mov Disord"},{"issue":"12","key":"2699_CR26","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn D, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689\u2013707 quiz 1837.","journal-title":"Mov Disord"},{"key":"2699_CR27","first-page":"153","volume-title":"Recent Developments in Parkinsons Disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton RI, Members of the UPDRS Development Committee. Unified Parkinson\u2019s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinsons Disease: Macmillan Health Care Information; 1987. p. 153\u201363. 293\u2013305."},{"issue":"6","key":"2699_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540\u20135.","journal-title":"Sleep"},{"issue":"15","key":"2699_CR29","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649\u201353.","journal-title":"Mov Disord"},{"issue":"5","key":"2699_CR30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ana.21991","volume":"67","author":"J Matthew","year":"2010","unstructured":"Matthew J, Thurtell M, Anand C, Joshi M, Alice C, Leone D, et al. Cross-over trial of gabapentin and Memantine as treatment for acquired Nystagmus. Ann Neurol. 2010;67(5):676\u201380.","journal-title":"Ann Neurol"},{"issue":"4","key":"2699_CR31","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/00000539-200010000-00036","volume":"91","author":"L Nikolajsen","year":"2000","unstructured":"Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg. 2000;91(4):960\u20136.","journal-title":"Anesth Analg"},{"issue":"5","key":"2699_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/jnnp.50.5.607","volume":"50","author":"J Bogousslavsky","year":"1987","unstructured":"Bogousslavsky J, Miklossy J, Deruaz JP, Assal G, Regli F. Lingual and fusiform gyri in visual processing: a clinico-pathologic study of superior altitudinal hemianopia. J Neurol Neurosurg Psychiatry. 1987;50(5):607\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5\u20136","key":"2699_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/(SICI)1097-0193(1998)6:5\/6<383::AID-HBM10>3.0.CO;2-Z","volume":"6","author":"GR Mangun","year":"1998","unstructured":"Mangun GR, Buonocore MH, Girelli M, Jha AP. ERP and fMRI measures of visual spatial selective attention. Hum Brain Mapp. 1998;6(5\u20136):383\u20139.","journal-title":"Hum Brain Mapp"},{"issue":"3","key":"2699_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/(SICI)1097-0193(200003)9:3<156::AID-HBM4>3.0.CO;2-Q","volume":"9","author":"WC Machielsen","year":"2000","unstructured":"Machielsen WC, Rombouts SA, Barkhof F, Scheltens P, Witter MP. fMRI of visual encoding: reproducibility of activation. Hum Brain Mapp. 2000;9(3):156\u201364.","journal-title":"Hum Brain Mapp"},{"key":"2699_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1365-2869.2010.00872.x","volume":"20","author":"C Nissen","year":"2011","unstructured":"Nissen C, Kloepfer C, Feige B, Piosczyk H, Spiegelhalder K, Voderholzer U, et al. Sleep-related memory consolidation in primary insomnia. J Sleep Res. 2011;20:129\u201336.","journal-title":"J Sleep Res"},{"issue":"Suppl 1","key":"2699_CR36","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S1389-9457(08)70014-5","volume":"9","author":"MP Walker","year":"2008","unstructured":"Walker MP. Cognitive consequences of sleep and sleep loss. Sleep Med. 2008;9(Suppl 1):S29\u201334.","journal-title":"Sleep Med"},{"issue":"1","key":"2699_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2047-783X-19-32","volume":"19","author":"Y Li","year":"2014","unstructured":"Li Y, Wang E, Zhang H, Dou S, Liu L, Tong L, et al. Functional connectivity changes between parietal and prefrontal cortices in primary insomnia patients: evidence from resting-state fMRI. Eur J Med Res. 2014;19(1):32.","journal-title":"Eur J Med Res"},{"issue":"2","key":"2699_CR38","first-page":"9","volume":"6","author":"I Masahiro","year":"2017","unstructured":"Masahiro I, Hiroshi K, Satoshi U. Can levodopa prevent cognitive decline in patients with Parkinson's disease? Am J Neurodegener Dis. 2017;6(2):9\u201314.","journal-title":"Am J Neurodegener Dis"},{"issue":"1","key":"2699_CR39","first-page":"13","volume":"28","author":"B Livia","year":"2013","unstructured":"Livia B, Valentina P, Maria CM, Raffaele B, Cesare I, Paolo S. The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Funct Neurol. 2013;28(1):13\u20137.","journal-title":"Funct Neurol"},{"issue":"5","key":"2699_CR40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/gps.1711","volume":"22","author":"S Ferris","year":"2007","unstructured":"Ferris S, Schneider L, Farmer M, Kay G, Crook T. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Int J Geriatr Psychiatry. 2007;22(5):448\u201355.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2699_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/postgradmedj-2015-133247","volume":"91","author":"J Cosgrove","year":"2015","unstructured":"Cosgrove J, Alty JE, Jamieson S. Cognitive impairment in Parkinson\u2019s disease. Postgrad Med J. 2015;91:212\u201320.","journal-title":"Postgrad Med J"},{"key":"2699_CR42","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","volume":"9","author":"AA Kehagia","year":"2010","unstructured":"Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease. Lancet Neurol. 2010;9:1200\u201313.","journal-title":"Lancet Neurol"},{"key":"2699_CR43","doi-asserted-by":"publisher","first-page":"33929","DOI":"10.1038\/srep33929","volume":"216","author":"BJ Lawrence","year":"2016","unstructured":"Lawrence BJ, Gasson N, Loftus AM. Prevalence and subtypes of mild cognitive impairment in Parkinson's disease. Sci Rep. 2016;216:33929.","journal-title":"Sci Rep"},{"issue":"6","key":"2699_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/mds.10417","volume":"18","author":"S Paus","year":"2003","unstructured":"Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease. Mov Disord. 2003;18(6):659\u201367.","journal-title":"Mov Disord"},{"issue":"2","key":"2699_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"H-F Wang","year":"2015","unstructured":"Wang H-F, Yu J-T, Tang S-W, Jiang T, Tan C-C, Meng X-F, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2699_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cortex.2017.05.021","volume":"93","author":"AC Simioni","year":"2017","unstructured":"Simioni AC, Dagher A, Fellows LK. Effects of levodopa on corticostriatal circuits supporting working memory in Parkinson\u2019s disease. Cortex. 2017;93:193\u2013205.","journal-title":"Cortex."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02699-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02699-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02699-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:59:52Z","timestamp":1700575192000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02699-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02699-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"13 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Nagoya City University Hospitals. All subjects gave written informed consent. This study was complied with national legislation and the Declaration of Helsinki guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}